How Can Investors Benefit from a Bear Market? | Christian Angermayer | PSYCH Symposium: London 2022

Drug developers have raised over US$2 billion, but can previous levels of investment be maintained? At PSYCH Symposium: London 2022, leading investor and Founder of atai Life Sciences, Christian Angermayer, discussed the future of psychedelic healthcare. About PSYCH: PSYCH is a data and insights platform for the psychedelic healthcare industry. As our collective understanding of and attitudes towards psychedelics shift dramatically, we are witnessing a global rise in clinical trials, academic research and commercial investment. PSYCH tracks key psychedelic players, innovations and milestones, providing market insights to help investors make informed decisions. Psychedelics are poised to disrupt the way we approach healthcare. To learn more about PSYCH, access our industry-leading events, subscribe to the most widely read psychedelics industry newsletter, or download The Psychedelics as Medicine Report. Web: https://psych.global/ Twitter:   / psychglobal_   LinkedIn:   / psyc.  .